Quick Answer
Zentalis Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $36.00 million for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +6.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $16.11 million | Q2 2019: $8.74 million | Q3 2019: $80.53 million | Q1 2020: $63.65 million | Q2 2020: $96.02 million | Q3 2020: $92.55 million | Q1 2021: $29.00 million | Q2 2021: $49.17 million | Q3 2021: $40.81 million | Q1 2022: $30.57 million | Q2 2022: $55.14 million | Q3 2022: $42.55 million | Q1 2023: $36.28 million | Q2 2023: $266.56 million | Q3 2023: $110.75 million | Q1 2024: $37.62 million | Q2 2024: $36.98 million | Q3 2024: $41.32 million | Q1 2025: $41.93 million | Q2 2025: $37.60 million | Q3 2025: $39.07 million.
- Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 46.5%.
- Historical annual values: Fiscal year 2025: $36.00 million | Fiscal year 2024: $33.90 million | Fiscal year 2023: $28.04 million | Fiscal year 2022: $43.07 million | Fiscal year 2021: $59.71 million | Fiscal year 2020: $54.95 million | Fiscal year 2019: $67.25 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: